Literature DB >> 33441747

Divergent immune landscapes of primary and syngeneic Kras-driven mouse tumor models.

Wade R Gutierrez1,2,3, Amanda Scherer3,4, Gavin R McGivney1,3, Qierra R Brockman3,5, Vickie Knepper-Adrian4, Emily A Laverty4, Grace A Roughton4, Rebecca D Dodd6,7,8,9,10.   

Abstract

Immune cells play critical functions in cancer, and mice with intact immune systems are vital to understanding tumor immunology. Both genetically engineered mouse models (GEMMs) and syngeneic cell transplant approaches use immunocompetent mice to define immune-dependent events in tumor development and progression. Due to their rapid and reproducible nature, there is expanded interest in developing new syngeneic tools from established primary tumor models. However, few studies have examined the extent that syngeneic tumors reflect the immune profile of their originating primary models. Here, we describe comprehensive immunophenotyping of two well-established GEMMs and four new syngeneic models derived from these parental primary tumors. To our knowledge, this is the first systematic analysis comparing immune landscapes between primary and orthotopic syngeneic tumors. These models all use the same well-defined human-relevant driver mutations, arise at identical orthotopic locations, and are generated in mice of the same background strain. This allows for a direct and focused comparison of tumor immune landscapes in carefully controlled mouse models. We identify key differences between the immune infiltrate of GEMM models and their corresponding syngeneic tumors. Most notable is the divergence of T cell populations, with different proportions of CD8+ T cells and regulatory T cells across several models. We also observe immune variation across syngeneic tumors derived from the same primary model. These findings highlight the importance of immune variance across mouse modeling approaches, which has strong implications for the design of rigorous and reproducible translational studies.

Entities:  

Year:  2021        PMID: 33441747      PMCID: PMC7806664          DOI: 10.1038/s41598-020-80216-1

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  52 in total

1.  IL-23 secreted by myeloid cells drives castration-resistant prostate cancer.

Authors:  Arianna Calcinotto; Clarissa Spataro; Elena Zagato; Diletta Di Mitri; Veronica Gil; Mateus Crespo; Gaston De Bernardis; Marco Losa; Michela Mirenda; Emiliano Pasquini; Andrea Rinaldi; Semini Sumanasuriya; Maryou B Lambros; Antje Neeb; Roberta Lucianò; Carlo A Bravi; Daniel Nava-Rodrigues; David Dolling; Tommaso Prayer-Galetti; Ana Ferreira; Alberto Briganti; Antonio Esposito; Simon Barry; Wei Yuan; Adam Sharp; Johann de Bono; Andrea Alimonti
Journal:  Nature       Date:  2018-06-27       Impact factor: 49.962

2.  Pathogenic and Targetable Genetic Alterations in Resected Recurrent Undifferentiated Pleomorphic Sarcomas Identified by Targeted Next-generation Sequencing.

Authors:  Biqiang Zheng; Yueting Qu; Jian Wang; Yingqiang Shi; Wangjun Yan
Journal:  Cancer Genomics Proteomics       Date:  2019 May-Jun       Impact factor: 4.069

3.  The local immune landscape determines tumor PD-L1 heterogeneity and sensitivity to therapy.

Authors:  Yuan Wei; Qiyi Zhao; Zhiliang Gao; Xiang-Ming Lao; Wei-Ming Lin; Dong-Ping Chen; Ming Mu; Chun-Xiang Huang; Zheng-Yu Liu; Bo Li; Limin Zheng; Dong-Ming Kuang
Journal:  J Clin Invest       Date:  2019-05-21       Impact factor: 14.808

4.  Distinct and overlapping sarcoma subtypes initiated from muscle stem and progenitor cells.

Authors:  Jordan M Blum; Leonor Añó; Zhizhong Li; David Van Mater; Brian D Bennett; Mohit Sachdeva; Irina Lagutina; Minsi Zhang; Jeffrey K Mito; Leslie G Dodd; Diana M Cardona; Rebecca D Dodd; Nerissa Williams; Yan Ma; Christoph Lepper; Corinne M Linardic; Sayan Mukherjee; Gerard C Grosveld; Chen-Ming Fan; David G Kirsch
Journal:  Cell Rep       Date:  2013-11-14       Impact factor: 9.423

5.  A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer.

Authors:  Melodi Javid Whitley; Diana M Cardona; Alexander L Lazarides; Ivan Spasojevic; Jorge M Ferrer; Joan Cahill; Chang-Lung Lee; Matija Snuderl; Dan G Blazer; E Shelley Hwang; Rachel A Greenup; Paul J Mosca; Jeffrey K Mito; Kyle C Cuneo; Nicole A Larrier; Erin K O'Reilly; Richard F Riedel; William C Eward; David B Strasfeld; Dai Fukumura; Rakesh K Jain; W David Lee; Linda G Griffith; Moungi G Bawendi; David G Kirsch; Brian E Brigman
Journal:  Sci Transl Med       Date:  2016-01-06       Impact factor: 17.956

6.  Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

Authors:  Weiyi Peng; Jie Qing Chen; Chengwen Liu; Shruti Malu; Caitlin Creasy; Michael T Tetzlaff; Chunyu Xu; Jodi A McKenzie; Chunlei Zhang; Xiaoxuan Liang; Leila J Williams; Wanleng Deng; Guo Chen; Rina Mbofung; Alexander J Lazar; Carlos A Torres-Cabala; Zachary A Cooper; Pei-Ling Chen; Trang N Tieu; Stefani Spranger; Xiaoxing Yu; Chantale Bernatchez; Marie-Andree Forget; Cara Haymaker; Rodabe Amaria; Jennifer L McQuade; Isabella C Glitza; Tina Cascone; Haiyan S Li; Lawrence N Kwong; Timothy P Heffernan; Jianhua Hu; Roland L Bassett; Marcus W Bosenberg; Scott E Woodman; Willem W Overwijk; Gregory Lizée; Jason Roszik; Thomas F Gajewski; Jennifer A Wargo; Jeffrey E Gershenwald; Laszlo Radvanyi; Michael A Davies; Patrick Hwu
Journal:  Cancer Discov       Date:  2015-12-08       Impact factor: 39.397

Review 7.  Genetically engineered mouse models in oncology research and cancer medicine.

Authors:  Kelly Kersten; Karin E de Visser; Martine H van Miltenburg; Jos Jonkers
Journal:  EMBO Mol Med       Date:  2017-02       Impact factor: 12.137

Review 8.  MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy.

Authors:  Annelisa M Cornel; Iris L Mimpen; Stefan Nierkens
Journal:  Cancers (Basel)       Date:  2020-07-02       Impact factor: 6.639

9.  Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas.

Authors:  Amanda R Dancsok; Dongxia Gao; Anna F Lee; Sonja Eriksson Steigen; Jean-Yves Blay; David M Thomas; Robert G Maki; Torsten O Nielsen; Elizabeth G Demicco
Journal:  Oncoimmunology       Date:  2020-04-12       Impact factor: 8.110

10.  Tumor location impacts immune response in mouse models of colon cancer.

Authors:  Xianda Zhao; Lihua Li; Timothy K Starr; Subbaya Subramanian
Journal:  Oncotarget       Date:  2017-06-09
View more
  1 in total

Review 1.  Emerging mechanisms of immunotherapy resistance in sarcomas.

Authors:  Vaia Florou; Breelyn A Wilky
Journal:  Cancer Drug Resist       Date:  2022-03-05
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.